Immunotherapies have been hot topics at the last two ASH and ASCO conferences. That trend didn’t let up at this year’s American Society of Hematology annual meeting in New Orleans.
New targeted therapy options headlined this year’s American Society of Hematology meetings in New Orleans this year. One example: new drugs for chronic lymphocytic leukemia (CLL) that are more effective and better tolerated.
I know, I know. It’s easy to become numb to the endless new cancer therapy developments that never seem to pan-out. Well, I believe this one is different. This is the real deal:
This is good news for those of us bone marrow/blood cancer victims who seem caught-up in perpetual chemotherapy. “They” call it maintenance. It’s expensive and there seems to be very little motivation to back-off or stop.
According to the bone marrow/stem cell transplant site, Marrow.org, ” melodysplastic syndromes (MDS) are a group of diseases that affect the bone marrow and blood. Some types of MDS are mild and easily managed, while other types are severe and life-threatening. Mild MDS can grow more severe over time. It can also develop into a fast-growing, severe leukemia called acute myelogenous leukemia.”
I am flying-off to Illinios today to cover the American Society of Clinical Oncology (ASCO) meetings in Chicago. Here is a summary of some of the exciting cancer therapy related news we can expect to learn about there this weekend:
I mentioned my impending stem cell transplant procedure a week or so ago. I would, once again, like to apologize for not getting our news updates out to you lately.
This is an interesting article I found on OncologySTAT a while back:
I thought it would be interesting to take a look at cancer research from an Asian perspective. Here is a an article from the Website of a major newspaper from India, AndhraNews.net:
OncologySTAT.com featured this Pink Sheet Daily article a few weeks ago. The fact there are several good, front-line chemo drugs for use against chronic myeloid leukemia is good news, but not the story here. This is a business story–a battle between drugs and drug companies. Read the first part of the article and see what you think:
Bristol’s Once-daily Sprycel Faces Off Against Novartis’ Tasigna After Clearance in First-line Leukemia
The Pink Sheet Daily. 2010 Oct 28, E Hayes
Millennium, a division of the Takeda Oncology Company in Japan, is a leading biopharmaceutical company based in Cambridge, Massachuesets. Millenium markets VELCADE, a proteasome inhibitor which is primarily used in multiple myeloma patients.
We can thank Biosciencetechnology.com for this report about continuing genetic research which may help treat some non-Hodgkin’s lymphoma patients:
Here is some leukemia/lymphoma news. The first is from sifiNews. Site name doesn’t fill you with confidence, does it?
The Cancer Network’s Chronic Myeloid Leukemia Resource Center offers a number of helpful links and updates about the latest treatment advances and therapy options.
Here is an exerpt from an article I saved last month, featuring more important work to help minority patients (and the rest of us!) by expanding collections of cord blood for those who need stem cell transplants:
From The Leukemia & Lymphoma Society, September 14th, 2010:
Here is a noteworthy article we found on Caring4Cancer.com today. This is an important trend, because it doesn’t only affect lymphoma patients. Lower dosing is a fortunate trend for patients fighting a number of different cancers:
Cancer Research UK recently said that people diagnosed with non-Hodgkin’s lymphoma, bowel, breast and ovarian cancer – cancers that are notoriously difficult to treat and sometimes end in death – are now surviving in numbers that double previous figures.
Here is some positive news for relapsed, high risk leukemia patients: